If I cant use injections, what are my options
An epidemiologic study by Apnimed, a clinical-stage pharmaceutical company developing AD109, an oral drug candidate for OSA, demonstrated that most people with OSA60.6%are not obese
To learn more about these market drivers, global ingredient supplier Corbion undertook two proprietary surveys of US consumers to learn more about how, and to what extent, food choices and expenditures are being affected by the prevalent use of GLP-1 medications
Surgical techniques will be aimed at delaying the rapid transit of the gastric reservoir to the intestine or at reconstructing the gastrointestinal tract to normal anatomy
Grow your brand, now and through patent expiry This blog is part of an ongoing series, A Brave New World: Therapeutic Area Deep Dives
Your provider will customize a plan that balances results, long-term success, and overall wellness rather than a one-size-fits-all timeline